The healthcare challenge
AKI is a frequent complication of severe conditions, in particular sepsis, and it increases the mortality rate of sepsis.
- About 13.3 million people worldwide are impacted*.
- Up to 60% of severely ill patients develop AKI, which can result in prolonged hospital stays, chronic kidney disease, a greater risk of mortality, and higher cost of care**.
Greater AKI severity is associated with increased mortality and AKI patients have worse renal function at the time of hospital discharge.
The role of diagnostics
AKI may be avoided if proper care is given early on. Early diagnosis and rapid management of patients at risk for AKI is therefore essential, since there is no specific treatment to reverse established AKI.
Currently, urine output and serum creatinine are the only two commonly used markers for kidney function. These two lagging indicators can take up to 6 or 24 hours, respectively, to indicate kidney injury.
In April 2018, bioMérieux announced the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases. The NEPHROCHECK® test was developed by Astute Medical. This innovative, predictive test for the early risk assessment of acute kidney injuries is FDA-cleared and CE-marked.
The NEPHROCHECK® Test is intended to be used as a risk assessment test in conjunction with clinical evaluation to aid in identifying those patients at risk for developing moderate or severe AKI within 12 hours of patient assessment.
* Zuk A & Bonventre JV, “Acute Kidney Injury”, Annu. Rev. Med. 2016. 67:293–307.
* Joannidis et al. Intensive Care Med 2009.